European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Palbociclib + aromatase inhibitor|DRUG: Aromatase inhibitor
Sponsor: Pfizer